Abstract: The present invention provides a method for the treatment of interferon resistant tumors through the use of recombinant vectors encoding interferon species. In particular it is noted that interferon species provided by recombinant vectors possesses properties not associated with the recombinantly produced interferon proteins. The present invention further provides compositions useful in the treatment of interferon resistant tumors using recombinant vectors encoding interferons.
Abstract: Oligonucleotides with activity in preventing poly(A) adenylation at intron 9 of the KCNH2 gene, as well as pharmaceutical compositions comprising the oligonucleotides and methods of using the oligonucleotides to treat long QT syndrome in a subject are disclosed. The oligonucleotides include antisense sequences corresponding to sites termed DSE-1 and DSE-2 in intron 9.
Type:
Grant
Filed:
January 20, 2015
Date of Patent:
September 6, 2016
Assignee:
OREGON HEALTH & SCIENCE UNIVERSITY
Inventors:
Zhengfeng Zhou, Qiuming Gong, Matthew Stump
Abstract: The present invention relates to stable lipid nanoparticle pharmaceutical formulations which are substantially free of large aggregates (e.g., aggregates greater than 1 ?m in size) and include a substantially non-ionic medium.
Abstract: The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.
Type:
Grant
Filed:
September 8, 2015
Date of Patent:
June 28, 2016
Assignee:
miRagen Therapeutics, Inc.
Inventors:
Rusty L. Montgomery, Christina M. Dalby, Eva Van Rooij, Corrie Gallant-Behm
Abstract: The present invention includes compositions and methods for making and using a bifunctional shRNAs capable of reducing an expression of a K-ras gene, e.g., a mutated K-ras gene, wherein at least one target site sequence of the bifunctional RNA molecule is located within the K-ras gene and wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of K-ras.
Type:
Grant
Filed:
May 9, 2013
Date of Patent:
May 31, 2016
Assignee:
STRIKE BIO, INC.
Inventors:
Donald Rao, Zhaohui Wang, John J. Nemunaitis, Neal Senzer
Abstract: The invention relates to nucleic acid aptamers binding specifically to factor H, to a method for obtaining same, and to the uses thereof, in particular for the purposes of purifying factor H.
Type:
Grant
Filed:
November 28, 2012
Date of Patent:
May 24, 2016
Assignee:
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Abstract: The invention relates to a method for providing neuroprotection comprising administering to a subject an effective amount of a miRNA or a variant thereof. By providing neuroprotection, stroke or ischemic stroke can be prevented and/or treated.
Type:
Grant
Filed:
November 5, 2012
Date of Patent:
April 19, 2016
Assignee:
KAOHSIUNG MEDICAL UNIVERSITY
Inventors:
Suh-Hang H Juo, Yung-Song Wang, Hsin-Yun Cheng
Abstract: The present disclosure describes oligomeric compounds having at least one bicyclic nucleoside attached to the 3? or 5? termini by a neutral internucleoside linkage and methods of using the oligomeric compounds. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
Abstract: Nuclease-resistant RNA aptamers are provided which are capable of neutralizing PDGFR? and are therefore useful in the diagnosis and/or therapy of PDGFR?-associated and hyperproliferative-associated diseases, such as cancer and primary tumor metastasis. RNA aptamers provided herein include a modified synthetic RNA sequence wherein at least one pyrimidine residue is modified to 2?-fluoropyrimidine. Pharmaceutical compositions and diagnostic kits comprising RNA aptamers are also provided.
Type:
Grant
Filed:
October 4, 2013
Date of Patent:
January 12, 2016
Assignee:
CONSIGLIO NAZIONALE DELLE RICERCHE
Inventors:
Laura Cerchia, Gerolama Condorelli, Vittorio De Franciscis
Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.
Type:
Grant
Filed:
September 3, 2014
Date of Patent:
December 22, 2015
Assignee:
Korea Research Institute of Bioscience and Biotechnology
Inventors:
Misun Won, Kyung-Sook Chung, Young Joo Kim, Hye Kyung Hong, Young Il Yeom, Chae Ok Yun, Yu-Kyoung Oh, Kyung Bin Song, Hee Gu Lee, Eun Young Song, Young Ho Kim, Moon Hee Kim, Kyeong-Eun Jung
Abstract: Provided herein are signal activatable molecular constructs for enzyme-assisted delivery of molecules and related components, such as a sensor domain, compositions, methods and systems.
Type:
Grant
Filed:
March 21, 2013
Date of Patent:
December 8, 2015
Assignees:
CALIFORNIA INSTITUTE OF TECHNOLOGY, CITY OF HOPE
Inventors:
Si-ping Han, William A. Goddard, III, Lisa Scherer, John J. Rossi
Abstract: In one aspect, a method is provided of inhibiting proliferation of a mammalian cell comprising introducing into said cell an effective amount of at least one at least one small interfering RNA agent (iRNA), wherein said iRNA comprises a nucleotide sequence of at least 15 nucleotides, wherein the nucleotide sequence comprises a seed region consisting of nucleotide positions 1 to 12, wherein position 1 represents the 5? end of the iRNA nucleotide sequence and wherein said seed region comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to six contiguous nucleotides within positions 1 to 12 of a nucleotide sequence, wherein position 1 represents the 5?end of the nucleotide sequence, wherein the nucleotide sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.
Type:
Grant
Filed:
June 14, 2007
Date of Patent:
December 1, 2015
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Peter S. Linsley, Janell Schelter, Julja Burchard, Lee Lim, Miho Kibukawa
Abstract: A method for providing antisense therapy which reduces the expression of clusterin to provide therapeutic benefits in the treatment of cancer comprising administering from 40 to 640 mg anti-clusterin antisense oligonucleotide to a patient in need of treatment for a cancer expressing clusterin is provided. The method may include administering chemotherapeutic agent or agents, radiotherapy, and/or hormone ablation therapy. The invention also encompasses pharmaceutical compositions formulated to provide a dosage of 40 to 640 mg, and use of antisense in formulating a medicament.
Abstract: Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating cancer of cell proliferative disorders. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.
Type:
Grant
Filed:
August 2, 2011
Date of Patent:
November 10, 2015
Assignee:
Beth Israel Deaconess Medical Center
Inventors:
Chiang Li, Johannes Fruehauf, Shuanglin Xiang
Abstract: The present invention concerns nanoparticles functionalized with duplex RNA for a variety of uses, including but not limited to gene regulation. More specifically, the disclosure provides a new strategy for conjugating RNA to a nanoparticle to achieve increased stability and activity.
Type:
Grant
Filed:
November 24, 2009
Date of Patent:
September 22, 2015
Assignee:
NORTHWESTERN UNIVERSITY
Inventors:
Chad A. Mirkin, David A. Giljohann, Dwight Seferos, Andrew E. Prigodich, Pinal C. Patel
Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 26 nucleobases which are complementary to human microRNAs selected from the group consisting of miR19b, miR21, miR122a, miR155 and miR375. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogs into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.
Type:
Grant
Filed:
April 4, 2014
Date of Patent:
September 15, 2015
Assignee:
Roche Innovation Center Copenhagen A/S
Inventors:
Joacim Elmén, Phil Kearney, Sakari Kauppinen
Abstract: The present invention relates to compositions and methods for inhibiting loss of a retinal ganglion cell in a subject, comprising non-invasively applying to the surface of the eye of the subject an ophthalmic composition comprising a therapeutically effective amount of at least one siRNA which down regulates expression of a target gene associated with loss of the retinal ganglion cell, thereby inhibiting loss of the retinal ganglion cell in the subject. The methods of the invention also relate to the use of chemically modified siRNA compounds possessing structural motifs which down-regulate the expression of human genes expressed in retinal tissue in the mammalian eye.
Type:
Grant
Filed:
March 17, 2014
Date of Patent:
September 1, 2015
Assignee:
Quark Pharmaceuticals, Inc.
Inventors:
Elena Feinstein, Evgenia Alpert, Igor Mett, Hagar Kalinski, Amir Bar-Ilan, Igor Spivak, Natanja Slager
Abstract: The present invention relates to vectorization of double stranded RNA oligonucleotides by cationic particles chosen from among surfactant micelles, block or non-block polymer micelles, cationic liposomes and niosomes, cationic oleosomes and cationic nanoemulsions, as well as from among cationic organic or inorganic particles and nanocapsules, and to the use of compositions comprising the association of at least one dsRNA and at least one cationic particle on skin models.
Abstract: Methods for introducing nucleic acids to cells via exosomes for use in gene modulation and therapy, such as for gene silencing and to introduce genetic material into cells to compensate for abnormal genes or to induce or repress a process in the recipient cell.